NZ598540A - Diagnostic composition comprising plasma cations having superior safety profile - Google Patents

Diagnostic composition comprising plasma cations having superior safety profile

Info

Publication number
NZ598540A
NZ598540A NZ598540A NZ59854010A NZ598540A NZ 598540 A NZ598540 A NZ 598540A NZ 598540 A NZ598540 A NZ 598540A NZ 59854010 A NZ59854010 A NZ 59854010A NZ 598540 A NZ598540 A NZ 598540A
Authority
NZ
New Zealand
Prior art keywords
diagnostic composition
compound
safety profile
superior safety
composition
Prior art date
Application number
NZ598540A
Other languages
English (en)
Inventor
Mikkel Thaning
Lars-Goran Wistrand
Ben Newton
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Publication of NZ598540A publication Critical patent/NZ598540A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0452—Solutions, e.g. for injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NZ598540A 2009-10-29 2010-10-28 Diagnostic composition comprising plasma cations having superior safety profile NZ598540A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09174413 2009-10-29
PCT/EP2010/066351 WO2011051387A1 (en) 2009-10-29 2010-10-28 Diagnostic composition comprising plasma cations having superior safety profile

Publications (1)

Publication Number Publication Date
NZ598540A true NZ598540A (en) 2014-03-28

Family

ID=43503035

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ598540A NZ598540A (en) 2009-10-29 2010-10-28 Diagnostic composition comprising plasma cations having superior safety profile

Country Status (21)

Country Link
US (1) US8815210B2 (enExample)
EP (1) EP2493511B1 (enExample)
JP (1) JP5335147B2 (enExample)
KR (1) KR101545045B1 (enExample)
CN (1) CN102596257B (enExample)
AU (1) AU2010311478B2 (enExample)
BR (1) BR112012009859B1 (enExample)
CA (1) CA2773685C (enExample)
CO (1) CO6531477A2 (enExample)
DK (1) DK2493511T3 (enExample)
ES (1) ES2435299T3 (enExample)
HR (1) HRP20130991T1 (enExample)
IL (1) IL218456A (enExample)
IN (1) IN2012DN02126A (enExample)
MX (1) MX2012005021A (enExample)
NZ (1) NZ598540A (enExample)
PL (1) PL2493511T3 (enExample)
PT (1) PT2493511E (enExample)
RU (1) RU2544113C2 (enExample)
WO (1) WO2011051387A1 (enExample)
ZA (1) ZA201203505B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO333914B1 (no) * 2011-12-21 2013-10-21 Ge Healthcare As Stabilisering av diagnostisk røntgensammensetning
CA2862495A1 (en) 2012-01-11 2013-07-18 Ge Healthcare As X-ray imaging contrast media with low iodine concentration and x-ray imaging process
US20160279269A1 (en) * 2013-03-27 2016-09-29 Ge Healthcare As Method and reagent for preparing a diagnostic composition
US10575744B2 (en) 2017-02-24 2020-03-03 Medtronic Cryocath Lp Pericardial balloon mapping
CN109876157B (zh) * 2019-02-27 2020-12-15 浙江大学 离子特异性滤膜/介孔硅的复合材料、纳米传感器及其产品和应用
CN120114620B (zh) * 2025-03-18 2025-12-09 海南普利制药股份有限公司 一种碘帕醇注射液及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO161368C (no) * 1982-11-08 1989-08-09 Nyegaard & Co As Roentgenkontrastmidler samt radiologiske preparater derav.
GB8906130D0 (en) * 1989-03-17 1989-05-04 Nycomed As Compositions
GB9020091D0 (en) 1990-09-14 1990-10-24 Nycomed As Contrast media
DE4344464A1 (de) * 1993-12-22 1995-06-29 Schering Ag Kaskadenpolymere mit Iodaromaten
GB9419203D0 (en) * 1994-09-23 1994-11-09 Nycomed Innovation Ab Contrast media
US8066970B2 (en) * 2006-05-11 2011-11-29 Ge Healthcare As Contrast agents
CN103980154B (zh) * 2007-07-12 2015-02-25 通用电气医疗集团股份有限公司 造影剂

Also Published As

Publication number Publication date
ES2435299T3 (es) 2013-12-18
US20120328522A1 (en) 2012-12-27
EP2493511A1 (en) 2012-09-05
IL218456A (en) 2015-08-31
CA2773685C (en) 2016-05-31
US8815210B2 (en) 2014-08-26
CN102596257A (zh) 2012-07-18
IN2012DN02126A (enExample) 2015-08-21
PT2493511E (pt) 2013-11-18
AU2010311478A1 (en) 2012-03-29
RU2012116882A (ru) 2013-12-10
JP2013509378A (ja) 2013-03-14
BR112012009859A2 (pt) 2016-08-30
HRP20130991T1 (hr) 2013-12-20
BR112012009859B1 (pt) 2019-10-22
KR101545045B1 (ko) 2015-08-17
RU2544113C2 (ru) 2015-03-10
AU2010311478B2 (en) 2015-09-24
PL2493511T3 (pl) 2014-05-30
CA2773685A1 (en) 2011-05-05
DK2493511T3 (da) 2013-11-25
MX2012005021A (es) 2012-06-19
CO6531477A2 (es) 2012-09-28
WO2011051387A1 (en) 2011-05-05
CN102596257B (zh) 2013-08-21
ZA201203505B (en) 2013-01-31
EP2493511B1 (en) 2013-10-16
IL218456A0 (en) 2012-04-30
KR20120091149A (ko) 2012-08-17
JP5335147B2 (ja) 2013-11-06

Similar Documents

Publication Publication Date Title
NZ598540A (en) Diagnostic composition comprising plasma cations having superior safety profile
NZ626988A (en) X-ray imaging contrast media with low iodine concentration and x-ray imaging process
AR075423A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos
MX2010003884A (es) Anticuerpo dirigido a la proteina lecitina similar a inmunoglobulina de union a acido sialico-15 relacionado con osteoclastos.
MX2012004420A (es) Compuestos de espiropiperidino y uso farmaceutico de los mismos para tratar diabetes.
EA201290026A1 (ru) Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
IN2012MN02923A (enExample)
UA104869C2 (uk) Фармацевтичні композиції, що містять ліганди рецептора дофаміну
MX2009005413A (es) Formas cristalinas del acido zoledronico.
SG149895A1 (en) Contrast agents for myocardial perfusion imaging
NZ620879A (en) A novel formulation of indomethacin
MX2009011898A (es) Composiciones y metodos para tratar trastornos asociados con retencion de sal o fluido.
NZ609719A (en) Pharmaceutical composition
MX2007010856A (es) Composicion farmaceutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cancer.
WO2009108376A3 (en) Contrast agents for applications including perfusion imaging
PH12015500252A1 (en) Niclosamide for the treatment of solid tumors
UA93393C2 (uk) 1,3-діоксанкарбонові кислоти
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
NZ610247A (en) Β-lactamase inhibitors and their use
IL208279A0 (en) Spiro (5,5,) undecane derivatives
MX2011012201A (es) Combinacion de un inhibidor de cinasa de fosfoinositida-3 y un compuesto anti-diabetico.
WO2012044783A3 (en) Method of achieving a thymosin beta 4 concentration in a human patient
TW200501946A (en) Pharmaceutical composition for the treatment of schizophrenia in a patient with overweight
PT2454266E (pt) Sal de citrato de 9e-15-(2-pirrolidin-1-il-etoxi)- 7,12,25-trioxa-19,21,24-triaza-tetraciclo- [18.3.1.1(2,5).1(14)18)]hexacosa- 1(24),2,4,9,14,16,18(26),20,22-nonaeno
MY160005A (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 28 OCT 2017 BY AJ PARK

Effective date: 20140806

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 OCT 2018 BY COMPUTER PACKAGES INC

Effective date: 20171003

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 OCT 2019 BY ANAQUA SERVICES

Effective date: 20180919

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 OCT 2020 BY ANAQUA SERVICES

Effective date: 20190918

LAPS Patent lapsed